<DOC>
	<DOCNO>NCT01048034</DOCNO>
	<brief_summary>Azacitidine prove prolonged overall survival patient high-risk MDS . Minor pilot study show treatment Azacitidine induce transfusion independency previous transfusion dependent patient low-risk MDS . This study evaluate effect Azacitidine transfusion dependent patient low-risk MDS ( IPSS low int-1 ) low risk CMML . Included patient first fail , consider eligible , treatment EPO +/- G-CSF . Our hypothesis Azacitidine lead transfusion independency group patient . Those patient respond treatment Azacitidine alone , give treatment combination Azacitidine EPO hypothesis Azacitidine restore sensitivity EPO .</brief_summary>
	<brief_title>Evaluation Azacitidine Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome ( MDS ) Chronic Myelomonocytic Leukemia ( CMML )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Must 18 year age time sign informed consent form MDS IPSS Low Int1 , mixed MDS/MPD ; either CMML &lt; 10 % marrow blast RARST Patients high intermediate probability response accord predictive model ( see HellstromLindberg et al , Br J Haematol 99:34451 1997 ) refractory EPO / darbepoetin ( equivalent &gt; 60 000 U EPO / week &gt; 8 week ) follow EPO + GCSF &gt; 8 week , biosimilar drug equipotent dos , EPO + GCSF upfront 8 week . Patients low probability response accord predictive model , could include without prior EPO/GCSF treatment Transfusion need &gt; 4 unit last 8 week , &gt; 8 unit last 26 week . Subject sign informed consent document . Men woman childbearing potential must use effective contraception , 3 month treatment . Pregnant lactating female . Patients eligible curative treatment Expected survival le 24 week . Symptomatic thrombocytopenia / active bleeding Patients JAK2 positive RARST eligible new investigational drug Serum biochemical value follow 1 . Serum creatinine &gt; 2.0 mg/dL ( 177 micromol/L ) 2 . Serum aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) alanine transaminase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) &gt; 3.0 x upper limit normal ( ULN ) 3 . Serum total bilirubin &gt; 1.5 mg/dL ( 26 micromol/L ) Uncontrolled systemic infection Considered capable follow study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Chronic myelomonocytic leukemia</keyword>
	<keyword>Transfusion therapy</keyword>
	<keyword>Transfusion dependency</keyword>
	<keyword>Hypomethylating therapy</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>DNA-methylation</keyword>
	<keyword>Epigenetic modification</keyword>
</DOC>